Étude des hémopathies malignes avec cellules chevelues

Although the nature of the underlying oncogenic events in HCL is unknown, the recent identification of BRAFV600E mutation in HCL represents a way to introduce BRAF inhibitors in the treatment of HCL patients, who are refectory to purine analogs.